PMID- 19323898
OWN - NLM
STAT- MEDLINE
DCOM- 20090522
LR  - 20090605
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 122
IP  - 5
DP  - 2009 Mar 5
TI  - Antithrombotic and antiplatelet therapies in relation to risk stratification in 
      patients with non-ST elevation acute coronary syndrome: insights from the 
      Sino-Global Registry of Acute Coronary Events.
PG  - 502-8
AB  - BACKGROUND: Antithrombotic and antiplatelet therapies have been proposed to treat 
      non-ST elevation acute coronary syndrome (NSTEACS), yet limited information is 
      available about their applications from a multicenter "real-world" clinical 
      procedure, especially in China. This study was undertaken to characterize the use 
      of antithrombotic and antiplatelet agents in relation to the risk levels of the 
      NSTEACS patients who were enrolled in Sino-Global Registry of Acute Coronary 
      Events (GRACEs) registry study. METHODS: We analyzed the data from 618 Chinese 
      NSTEACS patients stratified into low-(n = 151), intermediate-(n = 233), and 
      high-risk groups (n = 234) based on GRACE risk scores. The baseline 
      characteristics, clinical presentations, antithrombotic and antiplatelet agents 
      were recorded and compared among the three groups. RESULTS: The administration 
      rates of low-molecular-weight heparins (LMWHs) (86.08%) and thienopyridines 
      (85.92%) were higher whereas the administration rate of glycoprotein IIb/IIIa 
      inhibitor (1.78%) was much lower than those reported previously. Meanwhile, 
      within the first 24 hours of admission, the use of heparin/LMWHs in the high-risk 
      group was more than that in the intermediate- and low-risk groups (73.50% vs 
      63.09% vs 55.63%, P = 0.001). Furthermore, the combination of antithrombotic and 
      antiplatelet medications showed no significant differences in all groups. 
      CONCLUSIONS: In the "real world" practice of China, the antithrombotic and 
      antiplatelet therapies on NSTEACS are well adherent to the current guidelines 
      except for several gaps, such as the very low use of glycoprotein IIb/IIIa 
      inhibitor. Moreover, these antithrombotic and antiplatelet treatments usually 
      tend to be underused for the high-risk ones.
FAU - Zhang, Li-jie
AU  - Zhang LJ
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 
      China.
FAU - Chen, Yun-dai
AU  - Chen YD
FAU - Song, Xian-tao
AU  - Song XT
FAU - Zhao, Fu-hai
AU  - Zhao FH
FAU - Lu, Shu-zheng
AU  - Lu SZ
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Pyridines)
RN  - 0 (thienopyridine)
SB  - IM
CIN - Chin Med J (Engl). 2009 May 5;122(9):1120. PMID: 19493455
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Aged
MH  - Coronary Disease/*drug therapy
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Pyridines/therapeutic use
MH  - Registries
MH  - Risk Assessment
EDAT- 2009/03/28 09:00
MHDA- 2009/05/23 09:00
CRDT- 2009/03/28 09:00
PHST- 2009/03/28 09:00 [entrez]
PHST- 2009/03/28 09:00 [pubmed]
PHST- 2009/05/23 09:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2009 Mar 5;122(5):502-8.